ClinicalTrials.gg
CompletedNCT02600923Updated Jan 20, 2022Results posted

Palbociclib Plus Letrozole For Postmenopausal Women With HR(+) HER2(-) Advanced Breast Cancer For Whom Letrozole Is Deemed Appropriate

A Phase 3 interventional study of Palbociclib and Letrozole in Advanced Breast Cancer Female, sponsored by Pfizer. Completed at 24 sites in 4 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-01-20.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
131
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 111 studies testing palbociclib in Breast Neoplasms — 19 open to participants now, 43 under way, 9 of them phase 3. palbociclib · Breast Neoplasms.

Enrollment
47th of 111
131 · median 100
Started
2016
with 14 others
Phase 3
20 of 111
4 open now
Registered
30th of 111
by date
Lead sponsor
10 of 111
Pfizer

Among the 111 studies testing palbociclib in Breast Neoplasms, this one is the 47th largest by enrollment, is one of 15 that started in 2016, is one of 20 in phase 3, and was the 30th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

19 of the 111 studies testing palbociclib in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 19 open studies →

About palbociclib

palbociclib: first FDA approval 2015 (IBRANCE), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 111 studies testing palbociclib in Breast Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to provide access to palbociclib in Mexico and in selected Latin American countries before it becomes commercially available to patients with HR positive/HER2-negative ABC who are appropriate candidates for letrozole therapy.

03

Conditions studied

  • Advanced Breast Cancer Female

Browse trials for

Keywords

  • palbociclib, ibrance, breast cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult women with proven diagnosis of advanced adenocarcinoma of the breast (locoregional recurrent or disease).
  • Women who are not of .
  • ER-positive and/or Progesterone receptor (PgR)-positive tumor based on local laboratory results (test as per local practice).
  • -negative breast cancer based on local laboratory results (test as per local practice or local guidelines).
  • Patients must be appropriate candidates for letrozole therapy.
  • (ECOG) performance status 0-2.
  • Adequate bone marrow function.
  • Adequate liver function
  • Adequate renal function.

Exclusion criteria

Exclusion Criteria:

  • Known to letrozole, or any of its , or to any palbociclib excipients.
  • Current use of food or drugs known to be potent inhibitors or inducers of isoenzymes within 7 days prior to study entry.
  • Prior treatment with any CDK inhibitor.
  • Previous participation in a palbociclib clinical study.
  • Participation in other studies involving drug(s) within 2 weeks prior to study entry and/or during study participation.
  • >480 msec; history of QT syndrome, Brugada syndrome or known history of QTc prolongation, or Torsade de Pointes.
  • High cardiovascular risk, including, but not limited to recent myocardial infarction, severe/unstable angina and severe cardiac dysrhythmias in the past 6 months prior to enrollment.
  • Diagnosis of any second invasive within the last 3 years prior to enrollment. Note: patients with adequately treated basal cell or squamous cell skin cancer, a history of intraepithelial neoplasia or in situ disease (eg, carcinoma in situ of the cervix or melanoma in situ) may enter.
  • Active uncontrolled or symptomatic . Previously treated and clinically stable, brain metastases are permitted.
  • Other severe acute or chronic medical or psychiatric conditions.
  • Patients who are investigational site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or patients who are Pfizer employees directly involved in the conduct of the study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Masking
None (open label)
Enrollment
131 participants (actual)

Study arms

  • Experimental
    Palbociclib + Letrozole

    palbociclib and letrozole combination

    Drug: Palbociclib · Drug: Letrozole

Interventions

  • Palbociclib will be administered orally once a day at 125 mg/day for 21 days followed by 7 days off treatment for each 28-day cycle (Schedule 3/1).

    Also known as: Ibrance

  • Letrozole will be administered orally at 2.5 mg once daily as continuous daily dosing schedule according to product labeling and in compliance with its local prescribing information.

    Also known as: Femara

06

What researchers measure

Primary outcomes

  1. Number of Participants With All-causality Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product; the event did not need to have a causal relationship with the treatment. All AEs reported after initiation of study drug treatment were considered as TEAE. AE severity was graded according to Common Terminology Criteria for AEs (CTCAE) version 4.03. Grade 1 AEs are mild AEs; Grade 2 AEs are moderate AEs; Grade 3 AEs are severe AEs, Grade 4 AEs are life-threatening consequences and Grade 5 AEs are deaths related to AEs. Each AE was counted once for the participant in the most severe severity.

    Time frame: 3 years

  2. Number of Participants With Palbociclib-related TEAEs

    An AE was any untoward medical occurrence in a clinical investigation participant administered a product; the event did not need to have a causal relationship with the treatment. All AEs reported after initiation of study drug treatment were considered as TEAE. AE severity was graded according to CTCAE version 4.03. Grade 1 AEs are mild AEs; Grade 2 AEs are moderate AEs; Grade 3 AEs are severe AEs, Grade 4 AEs are life-threatening consequences and Grade 5 AEs are deaths related to AEs. Palbociclib-related TEAEs were determined by the investigator.

    Time frame: 3 years

  3. Number of Participants With Serious Adverse Events (SAEs)

    An SAE was any untoward medical occurrence at any dose that resulted in death; was life threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in congenital anomaly/birth defect. AEs included both SAEs and AEs. Palbociclib-related SAEs were determined by the investigator.

    Time frame: 3 years

Secondary outcomes

  1. Number of Participants With Death

    Death from any cause while on treatment and within 28 days of palbociclib discontinuation was only counted below.

    Time frame: 3 years

  2. The Objective Response Rate (ORR)

    The tumor response was based on the response reported by investigator per local practice. No response confirmation was applied. ORR was defined as the percentage of participants with complete response or partial response relative to all as-treated population.

    Time frame: 3 years

07

Results

Posted May 21, 2020

Participant flow

Participant flow — Overall Study
MilestonePalbociclib+Letrozole
Started131
Treated130
Completed0
Not completed131
Withdrew: Death10
Withdrew: Adverse event3
Withdrew: Global deterioration of health status2
Withdrew: Insufficient clinical response6
Withdrew: Lost to follow-up1
Withdrew: Withdrawal by subject5
Withdrew: Objective progression or relapse50
Withdrew: Study terminated by sponsor53
Withdrew: Not treated1

Outcome measures

PrimaryNumber of Participants With All-causality Treatment-emergent Adverse Events (TEAEs)

An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product; the event did not need to have a causal relationship with the treatment. All AEs reported after initiation of study drug treatment were considered as TEAE. AE severity was graded according to Common Terminology Criteria for AEs (CTCAE) version 4.03. Grade 1 AEs are mild AEs; Grade 2 AEs are moderate AEs; Grade 3 AEs are severe AEs, Grade 4 AEs are life-threatening consequences and Grade 5 AEs are deaths related to AEs. Each AE was counted once for the participant in the most severe severity.

Time frame:
3 years
Reported as:
Count of participants · Participants
Number of Participants With All-causality Treatment-emergent Adverse Events (TEAEs)
ParticipantsPalbociclib+Letrozole
Grade 10
Grade 217
Grade 382
Grade 423
Grade 57
PrimaryNumber of Participants With Palbociclib-related TEAEs

An AE was any untoward medical occurrence in a clinical investigation participant administered a product; the event did not need to have a causal relationship with the treatment. All AEs reported after initiation of study drug treatment were considered as TEAE. AE severity was graded according to CTCAE version 4.03. Grade 1 AEs are mild AEs; Grade 2 AEs are moderate AEs; Grade 3 AEs are severe AEs, Grade 4 AEs are life-threatening consequences and Grade 5 AEs are deaths related to AEs. Palbociclib-related TEAEs were determined by the investigator.

Time frame:
3 years
Reported as:
Count of participants · Participants
Number of Participants With Palbociclib-related TEAEs
ParticipantsPalbociclib+Letrozole
Grade 12
Grade 225
Grade 381
Grade 420
Grade 50
PrimaryNumber of Participants With Serious Adverse Events (SAEs)

An SAE was any untoward medical occurrence at any dose that resulted in death; was life threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in congenital anomaly/birth defect. AEs included both SAEs and AEs. Palbociclib-related SAEs were determined by the investigator.

Time frame:
3 years
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events (SAEs)
ParticipantsPalbociclib+Letrozole
All-causality32
Palbociclib-related6
SecondaryNumber of Participants With Death

Death from any cause while on treatment and within 28 days of palbociclib discontinuation was only counted below.

Time frame:
3 years
Reported as:
Count of participants · Participants
Number of Participants With Death
ParticipantsPalbociclib+Letrozole
Number of Participants With Death5
SecondaryThe Objective Response Rate (ORR)

The tumor response was based on the response reported by investigator per local practice. No response confirmation was applied. ORR was defined as the percentage of participants with complete response or partial response relative to all as-treated population.

Time frame:
3 years
Reported as:
Number · percentage of evaluable participants
The Objective Response Rate (ORR)
percentage of evaluable participantsPalbociclib+Letrozole
The Objective Response Rate (ORR)24.8 (17.6 to 33.2)

Adverse events

Collected over 3 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Palbociclib+Letrozole10/130 (7.7%)32/130 (24.6%)129/130 (99.2%)
Most frequent serious events
Showing 10 of 36
Most frequent serious events
EventPalbociclib+Letrozole
PneumoniaInfections and infestations3/130
Disease progressionGeneral disorders2/130
TuberculosisInfections and infestations2/130
Femur fractureInjury, poisoning and procedural complications2/130
Back painMusculoskeletal and connective tissue disorders2/130
Deep vein thrombosisVascular disorders2/130
AnaemiaBlood and lymphatic system disorders1/130
Febrile neutropeniaBlood and lymphatic system disorders1/130
NeutropeniaBlood and lymphatic system disorders1/130
PancytopeniaBlood and lymphatic system disorders1/130
Most frequent other events
Showing 10 of 41
Most frequent other events
EventPalbociclib+Letrozole
NeutropeniaBlood and lymphatic system disorders91/130
LeukopeniaBlood and lymphatic system disorders45/130
AnaemiaBlood and lymphatic system disorders44/130
Neutrophil count decreasedInvestigations36/130
ThrombocytopeniaBlood and lymphatic system disorders32/130
DiarrhoeaGastrointestinal disorders30/130
ArthralgiaMusculoskeletal and connective tissue disorders26/130
NauseaGastrointestinal disorders25/130
HeadacheNervous system disorders25/130
White blood cell count decreasedInvestigations23/130

Baseline characteristics

Baseline analysis population included all participants who received at least 1 dose of palbociclib treatment.

Age, Categorical
Age, Categorical(Participants)Palbociclib+Letrozole
<=18 years0
Between 18 and 65 years89
>=65 years41
Sex: Female, Male
Sex: Female, Male(Participants)Palbociclib+Letrozole
Female130
Male0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Palbociclib+Letrozole
Hispanic or Latino130
Not Hispanic or Latino0
Unknown or Not Reported0
08

Study locations

24 sites
  • Instituto de Oncologia de Rosario
    Rosario, Santa FE S2000KZE, Argentina
  • Sanatorio Guemes
    Caba, C1180AAX, Argentina
  • Hospital Italiano de Buenos Aires
    Caba, C1181ACH, Argentina
  • Hospital Britanico de Buenos Aires
    Caba, C1280AEB, Argentina
  • Instituto Medico Especializado Alexander Fleming
    Caba, C1426ANZ, Argentina
  • Instituto de Cardiologia y Cirugia Cardiovascular
    Santa Fe, S3000EPV, Argentina
  • ISIS Centro Especializado
    Santa Fe, S3000FFU, Argentina
  • Hospital Da Cidade De Passo Fundo
    Passo Fundo, RIO Grande DO SUL 99010-260, Brazil
  • Hospital Sao Lucas da PUCRS / Uniao Brasileira de Educacao e Assistencia
    Porto Alegre, RIO Grande DO SUL 90610-000, Brazil
  • Oncologia Rede D'Or S.A.
    Rio de Janeiro, 22271-110, Brazil
  • IDOR - Instituto D'Or em Pesquisa e Ensino
    Rio de Janeiro, 22281-100, Brazil
  • Sociedade Beneficente de Senhoras Hospital Sirio Libanes
    Sao Paulo, 01308-050, Brazil
  • Clínica de Pesquisa e Centro de Estudos em Oncologia Ginecológica e Mamária Ltda
    São Paulo, 01317-000, Brazil
  • Instituto de Cancerologia S.A.
    Medellin, Antioquia 050034, Colombia
  • Oncomedica S.A.
    Monteria, Cordoba 230003, Colombia
  • Administradora Country
    Bogota, Distrito Capital 11001000, Colombia
  • Oncology Center
    Bogota, Distrito Capital 110221162, Colombia
  • Imagenes Diagnosticas
    Pereira, Risaralda 660001, Colombia
  • ONCOLOGOS DEL OCCIDENTE S.A.S Sede Pereira Clinica de Alta Tecnologia Maraya
    Pereira, Risaralda 660001, Colombia
  • Fucam A.C.
    Coyoacan, D.f. 04890, Mexico
  • Instituto Nacional de Cancerologia
    Tlalpan, D.f. 14080, Mexico
  • Hospital Maria Auxiliadora
    Guadalajara, Jalisco 44540, Mexico
  • Clinica de Especialidades Medicas Intepro, ONCE Oncologia Especializada
    Zapopan, Jalisco 45030, Mexico
  • Hospital Universitario Dr. Jose Eleuterio Gonzalez
    Monterrey, Nuevo LEON 64460, Mexico
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2016 to primary completion in May 2019, 37 months.

Results were first posted in May 2020, 11 months after primary completion.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 37 months is close to that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2015
First posted
Nov 9, 2015
StartActual
Apr 15, 2016
Primary completionActual
May 28, 2019
CompletionActual
May 28, 2019
Results first posted
May 21, 2020
Last update
Jan 20, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02600923
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Nov 9, 2015
Start date
Apr 15, 2016
Primary completion
May 28, 2019
Completion
May 28, 2019
Results posted
May 21, 2020
Last update
Jan 20, 2022

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Palbociclib · Letrozole

Start the discussion